Stem Cell Researchers Appalled As Judge Blocks Loosened Guidelines
This article was originally published in The Pink Sheet Daily
"Stunned" by the judgment, NIH Director Francis Collins believes it will stall innovation in the regenerative medicine arena.
You may also be interested in...
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. Earlier stage biotechs are trying to turn their platforms into research revenue as they look to non-profit, government, and private funding sources to advance their preclinical therapeutic programs. Whatever the model, worries abound that the financial woes of the next couple of years could blunt hard-earned momentum.
Academic researchers will benefit from access to federal funding, while benefits to industry may be less immediate.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.